

Drug Monograph

Drug/Drug Class: **Lidovir™ (acyclovir and lidocaine hydrochloride) Ointment Compounding Kit / Antiviral and Analgesic Agent**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each kit contains 2.48 g of acyclovir, 2.48 g of lidocaine HCl, and 57.2 g of white petrolatum.

Manufacturer: Allegis Pharmaceuticals, LLC Canton, MS 39046

Indications: Lidovir™ is used topically for pain associated with external viral infection as instructed by a physician.

Costs: \$ 119.50 per kit of Lidovir™ . Wholesale Acquisition Cost

Summary of Findings: MO HealthNet Division recommends Open Access status for this product.

Status Recommendation:

<input type="checkbox"/> Prior Authorization (PA) Required	<input checked="" type="checkbox"/> Open Access
<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Preferred Agent
<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> No PA Required

Prepared By: Skander Yalaoui, Pharm. D. Candidate
Date: July 17, 2012